You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RET-rearranged NSCLC

Showing 1 - 25 of 3,638
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)

Terminated
Has Results
  • ALK-positive Non-small Cell Lung Cancer (NSCLC)
  • +2 more
  • Irvine, California
  • +3 more
Aug 30, 2021

NSCLC, NSCLC Metastatic, NSCLC Recurrent Trial in Worldwide (Alectinib)

Terminated
  • Non-small Cell Lung Cancer
  • +2 more
  • Brussels, Belgium
  • +18 more
Aug 23, 2022

Advanced Nonhaematologic Malignancies Trial in Worldwide (BOS172738)

Active, not recruiting
  • Advanced Nonhaematologic Malignancies
  • Philadelphia, Pennsylvania
  • +20 more
Sep 23, 2022

NSCLC Trial in Shanghai (SY-5007)

Recruiting
  • Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Sep 4, 2023

Solid Tumor, Medullary Thyroid Cancer Trial in China (Selpercatinib)

Active, not recruiting
Has Results
  • Solid Tumor
  • Medullary Thyroid Cancer
  • Guangzhou, Guangdong, China
  • +12 more
May 9, 2022

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

NSCLC Trial in Guangzhou (HA121-28 tablet)

Recruiting
  • NSCLC
  • HA121-28 tablet
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Centre
Aug 2, 2022

Nonsmall Cell Lung Cancer Trial in Goyang-Si (Lorlatinib)

Recruiting
  • Nonsmall Cell Lung Cancer
  • Goyang-Si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
Apr 4, 2022

NSCLC Stage IIIB, ALK Gene Mutation Trial in Mexico City (Alectinib Oral Product)

Recruiting
  • Non-small Cell Lung Cancer Stage IIIB
  • ALK Gene Mutation
  • Alectinib Oral Product
  • Mexico City, Mexico
    Thoracic Oncology Unit and Personalized Medicine Laboratory, Ins
Jan 26, 2023

ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy Trial in Changsha (Pembrolizumab Combined With Bevacizumab and

Not yet recruiting
  • ALK Gene Mutation
  • +2 more
  • Pembrolizumab Combined With Bevacizumab and Chemotherapy
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Jul 14, 2022

Non Small Cell Lung Cancer Trial in Changsha (IBI-322 Plus Lenvatinib and Platinum)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • IBI-322 Plus Lenvatinib and Platinum
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 14, 2022

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion

Recruiting
  • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 1, 2022

    NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +5 more
    • Toripalimab
    • +3 more
    • Guanzhou, Guangdong, China
      Guangdong Lung Cancer Institute, Guangdong Provincial People's H
    Apr 4, 2023

    Chemotherapy Combined With Immunotherapy or Chemotherapy

    Completed
    • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Mar 9, 2022

    NSCLC Trial in Guangzhou (Ensartinib, Bevacizumab)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Aug 4, 2022

    Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell

    Recruiting
    • Locally Advanced Lung Non-Small Cell Carcinoma
    • +9 more
    • Duarte, California
    • +4 more
    Aug 17, 2022

    Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer Trial in Worldwide (Selpercatinib)

    Available
    • Non Small Cell Lung Cancer
    • +6 more
    • Goodyear, Arizona
    • +67 more
    Aug 17, 2022

    NSCLC Trial in United States (brigatinib)

    Terminated
    Has Results
    • Non-Small Cell Lung Cancer
    • Denver, Colorado
    • +3 more
    Jan 10, 2023

    Pralsetinib to Best Available Therapy in RET-Fusion Positive

    Enrolling by invitation
    • RET-fusion Non Small Cell Lung Cancer
    • +16 more
      • New York, New York
      • +2 more
      Aug 9, 2021

      Resistance-associated Mutations in Metastatic Lung Cancer

      Recruiting
      • Lung Cancer
      • Liquid biopsy
      • Monza, MB, Italy
        Fondazione IRCCS San Gerardo dei Tintori
      Oct 10, 2023

      NSCLC Trial in Boston (Alectinib, Cobimetinib)

      Recruiting
      • Non-small Cell Lung Cancer
      • Boston, Massachusetts
        Massachusetts general Hospital
      Mar 7, 2021

      NSCLC (NSCLC) Trial in Boston (Lorlatinib)

      Recruiting
      • Non-Small Cell Lung Cancer (NSCLC)
      • Boston, Massachusetts
        Massachusetts general Hospital
      Mar 7, 2021

      NSCLC, ALK Gene Rearrangement Positive Trial in France (RNAseq)

      Recruiting
      • Non-small Cell Lung Cancer
      • ALK Gene Rearrangement Positive
      • RNAseq
      • Saint-Denis, La Réunion, France
      • +44 more
      Nov 4, 2021

      NSCLC Trial in Worldwide (Selpercatinib, Carboplatin, Cisplatin)

      Active, not recruiting
      • Non-Small Cell Lung Cancer
      • Berazategui, Buenos Aires, Argentina
      • +195 more
      Jan 30, 2023